- Home
- SUUN vs NRXP Comparison
SUUN vs NRXP Comparison
Compare SUUN & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SUUN | NRXP |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.0M | 63.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SUUN | NRXP |
|---|---|---|
| Price | $1.96 | $2.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $5.00 | ★ $30.50 |
| AVG Volume (30 Days) | ★ 1.1M | 510.2K |
| Earning Date | 02-13-2026 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $32,753,484.00 | $242,000.00 |
| Revenue This Year | $127.67 | N/A |
| Revenue Next Year | $4.98 | $821.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.23 | $1.40 |
| 52 Week High | $6.43 | $6.01 |
Technical Indicators
Market Signals| Indicator | SUUN | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 66.62 | 53.36 |
| Support Level | $1.56 | $1.96 |
| Resistance Level | $2.18 | $2.52 |
| Average True Range (ATR) | 0.18 | 0.17 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 72.50 | 85.71 |
Price Performance
Historical ComparisonAbout SUUN SolarBank Corporation
SolarBank Corp is an independent renewable and clean energy project developer, power producer, and asset operator in Canada and the United States, with the majority of its revenue coming from the United States. The Company operates through two reportable segments: Development and EPC, which involves the development and construction of solar photovoltaic power projects, and IPP Production, which includes the operation of solar power and battery energy storage systems. Corporate and other activities cover operation, maintenance, and repairs. The majority of revenue is generated from the Development and EPC segment.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.